T-cell lymphoma-associated STAT3 variants impose a type 1 regulatory-like phenotype

Area of Science:

• Immunology
• Molecular Biology
• Cancer Biology

Background:

• Signal Transducer and Activator of Transcription 3 (STAT3) is crucial for T-cell function, regulating metabolism, apoptosis, and effector differentiation.
• STAT3 mutations are common in T-cell cancers, suggesting a role in malignancy development.
• Aberrant STAT3 signaling can mobilize pathways that promote cancer growth.

Purpose of the Study:

• To compare the cellular and molecular effects of two common cancer-associated STAT3 variants (Y640F and N647I).
• To elucidate the mechanisms by which STAT3 mutations drive T-cell cancers.
• To identify potential therapeutic targets by understanding how STAT3 mutations impact T-cell function.

Main Methods:

• Utilized a retrogenic system in mouse models to study STAT3 variants.
• Performed cellular and molecular-level comparisons of STAT3 Y640F and N647I mutants.
• Analyzed gene expression patterns, including the induction of specific gene programs.

Main Results:

• STAT3 variants Y640F and N647I exhibit gain-of-function phenotypes, with Y640F showing broader transcriptome-wide effects.
• Common STAT3 mutants induce a T regulatory 1 (Tr1) gene program, characterized by IL-10, LAG3, and CD39 expression.
• "Tr1 skewing" was observed in both mouse models and human T-cell malignancies.

Conclusions:

• Cancer-associated STAT3 mutations promote T-cell malignancies through a gain-of-function mechanism.
• The induced Tr1 gene program confers anti-inflammatory properties, potentially aiding cancer cell persistence and immune evasion.
• Understanding STAT3's role in T-cell cancers offers insights into novel therapeutic strategies targeting immune suppression.